Researchers identify bone-forming cells as the driver of scoliosis caused by a genetic disorder, which can be prevented ...
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...
BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on ...
News-Medical.Net on MSN
RAS-MAPK inhibition halts spinal deformity in neurofibromatosis type 1 mouse model
Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people.
RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) ...
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eli ...
(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...
The Wall Street Journal report added that Revolution Medicines would bolster AbbVie's efforts to build its presence in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback